Evidence map›Paper›PMID 28467426›Full record

ArticlePloS one2017

PKBγ/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia.

Kristy R Howell, Kirsten Floyd, Amanda J Law

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Selective orexin receptor cross-over treatment increases resilience and expression of neuroplastic signaling genes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. CRL4EMBO reports · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kristy R HowellDepartment of Psychiatry, School of Medicine, University of Colorado, Aurora, Colorado, United States of America.ORCID http://orcid.org/0000-0002-0872-5335
Kirsten FloydDepartment of Psychiatry, School of Medicine, University of Colorado, Aurora, Colorado, United States of America.
Amanda J LawDepartment of Psychiatry, School of Medicine, University of Colorado, Aurora, Colorado, United States of America.
University of Colorado Anschutz Medical Campus · US

Funding

Development of Psychopathology, Psychobiology, & BehaviorT32MH015442 · NIMH · UNIVERSITY OF COLORADO DENVER · PI JASON R TREGELLAS · 1985 to 2026
$10.2M
Targets for treating schizophrenia: AKT in neurodevelopment and cognition.R01MH103716 · NIMH · UNIVERSITY OF COLORADO DENVER · PI LAW, AMANDA JAYNE · 2014 to 2018
$2.1M
NIMH NIH HHS R01 MH103716NIMH NIH HHS T32 MH015442
6 · The paper itself

Abstract

Psychiatric genetic studies have identified genome-wide significant loci for schizophrenia. The AKT3/1q44 locus is a principal risk region and gene-network analyses identify AKT3 polymorphisms as a constituent of several neurobiological pathways relevant to psychiatric risk; the neurobiological mechanisms remain unknown. AKT3 shows prenatal enrichment during human neocortical development and recurrent copy number variations involving the 1q43-44 locus are associated with cortical malformations and intellectual disability, implicating an essential role in early brain development. Here, we investigated the role of AKT3 as it relates to aspects of learning and memory and behavioral function, relevant to schizophrenia and cognitive disability, utilizing a novel murine model of Akt3 genetic deficiency. Akt3 heterozygous (Akt3-/+) or null mice (Akt3-/-) were assessed in a comprehensive test battery. Brain biochemical studies were conducted to assess the impact of Akt3 deficiency on cortical Akt/mTOR signaling. Akt3-/+ and Akt3-/- mice exhibited selective deficits of temporal order discrimination and spatial memory, tasks critically dependent on intact prefrontal-hippocampal circuitry, but showed normal prepulse inhibition, fear conditioned learning, memory for novel objects and social function. Akt3 loss-of-function, reduced brain size and dramatically impaired cortical Akt Ser473 activation in an allele-dose dependent manner. Such changes were observed in the absence of altered Akt1 or Akt2 protein expression. Concomitant reduction of the mTORC2 complex proteins, Rictor and Sin1 identifies a potential mechanism. Our findings provide novel insight into the neurodevelopmental role of Akt3, identify a non-redundant role for Akt3 in the development of prefrontal cortical-mediated cognitive function and show that Akt3 is potentially the dominant regulator of AKT/mTOR signaling in brain.

Indexed as

Signal TransductionAnimalsConditioning, ClassicalFearLearning DisabilitiesLocomotionMechanistic Target of Rapamycin Complex 2Memory DisordersMiceMultiprotein ComplexesProto-Oncogene Proteins c-aktSchizophreniaTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 2Multiprotein ComplexesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID28467426
PMCPMC5414975
OpenAlexW2611814985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.